Rubicon Research Ltd (RUBICON) is currently trading at 1,833.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Rubicon Research Limited is a pharmaceutical company specializing in research, development, and manufacturing of specialty drugs and medical formulations for regulated markets, especially the US. The company experienced significant financial growth, with revenue up by 51.7% and profit after tax increasing by 91.2% year-over-year in Q3 FY26. These results reflect its broad-based product revenue strategy. Focus on specialty, drug-device combinations and complex generics is bolstered by extensive manufacturing capabilities in Maharashtra and a strategic acquisition of Pithampur facility from Alkem Laboratories to enhance capacity. Rubicon's diversified portfolio, with approvals for unique and high-demand products like nasal sprays, showcases its innovation-driven model and commitment to addressing unmet medical needs. The company's efficient capital deployment for R&D and operations is evidenced by high R&D productivity, with increasing returns on investment leading to strong growth prospects.

Over the past 52 weeks, Rubicon Research Ltd has traded between a low of ₹571.00 and a high of ₹1,896.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Rubicon Research Ltd has a market capitalization of approximately 30,430.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Rubicon Research Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 105.58 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 30,430.56 Cr, Rubicon Research Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Rubicon Research Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Rubicon Research Ltd is 105.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The disclosure in the provided text states General Atlantic Singapore RR Pte. Ltd. disposed of 1,40,00,000 equity shares over Aug 25-26, 2026.

The text cites an 8.45% stake sale over Aug 25-26, 2026, and also describes the Aug 26 block deals as roughly 8.4% (about 8.37% to 8.38%).

Consolidated revenue from operations was ₹534.34 crore (+51.6% YoY) and PAT was ₹84.78 crore (+95.8% YoY) for Q1FY27.

For the quarter ended June 2026, sales were ₹534.34 crore and net profit was ₹84.78 crore, as per the figures provided.